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ess: imen.aissa@rns.tnSummary Gemcitabine considered is to be a well-tolerated cytostatic drug with
little known side effects. Cutaneous reactions are well known but still rarely
reported.
We report the case of a 75-year-old man with stage IV non-small-cell lung
carcinoma treated with combination of gemcitabine 1000mg/m2 and cisplatin
75mg/m2 repeated every 28 days, who developed bilateral cutaneous bullous lesions
of lower limbs following gemcitabine administration. Histopathologic examination
did not show any toxidermy aspect and there was not any sign of immunoglobulin
deposit in direct immunofluorescence test. Chemotherapy was stopped and lesions
disappeared without any treatment. Even delayed with regard to gemcitabine
administration, the causal relationship of gemcitabine treatment with skin reaction
is possible according to the Naranjo probability scale. Pathologists should be aware
of this kind of side effect in managing chemotherapy drugs and report any
dermatologic reactions in order to identify the cause of toxicity and avoid a
misdiagnosis.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Gemcitabine is the hydrochloride salt of a deox-
ycytidine analogue, with demonstrated antineopla-
sic activity against solid tumours and thus againstElsevier Ltd. All rights reserv
3 55 405;
(A. Imen).non-small-cell lung cancer, when used either alone
or in combination with platinum compounds.1–3
Gemcitabine has a relative lack of side effects,
including nausea, emesis, myelosuppression, per-
ipheral oedema and pulmonary toxicity.1,4
Previous reports have shown that gemcitabine
had little cutaneous toxicities, such as alopecia and
maculopapular rash.5 Nevertheless, other kinds of
skin adverse effects still being sparsely reported.ed.
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reaction and discuss the causal relationship.Case report
A 75-year-old man was diagnosed as having stage IV
non-small-cell lung carcinoma with suprarenal
metastasis. Palliative chemotherapy with intrave-
nous gemcitabine 1000mg/m2 on days 1, 8 and 15
coupled with intravenous cisplatin on day 15,
repeated every 28 days was begun in September
2003. The two first cycles were conducted without
incidents.
On day 8 of the third cycle and before gemcita-
bine administration, the patient presented cough
with peripheral legs oedema. The drug administra-
tion was delayed. When hospitalised 4 days after,
physical examination of the patient revealed
bilateral oedema of lower legs with 3 cm diameter
bubble of the anterior face of right lower leg and
numerous little bubbles of the left one (Fig. 1). A
skin biopsy specimen taken from the bullous lesion
completed with direct immunofluorescence study
showed no toxidermy aspect with no sign of
fluorescence with immunoglobulin G (IgG), IgA or
IgM. To explore legs oedema aetiology, the labora-
tories studies revealed normal serum kidney
parameters (urea ¼ 2.52mmol/l, creatinine ¼
65.2 mmol/l, creatinine clearance ¼ 93.3ml/min
when measured with cockcroft and Gault method)Figure 1 Skin bullous of right leg above and left leg
below.and normal serum liver enzymes (aspartate amino-
transferase ¼ 25.5 UI/l, alanine aminotransferase
¼ 8.5 UI/l and INR ¼ 1); cardiac echography was
also normal.
An abdominal and pelvic echography showed no
abnormalities others than metastatic suprarenal
localisation.
Inquire of pharmacological imputability showed
no causal relationship between gemcitabine and
skin reaction because of delayed time of lesions
appearance of 12 days.
Skin lesions disappeared without specific treat-
ment, and during follow-up, the patient died
because of the progression of the disease.Discussion
There is some hypothesis that could explain skin
lesions occurrence during chemotherapeutic
agents’ administration in cancer patients, e.g.
cutaneous metastasis from the primary cancer,
paraneoplasic syndrome or a drug reaction.6
In the described patient, a drug skin reaction
seems most probable since histopathologic exam-
ination is normal. The accused drugs are gemcita-
bine and cisplatin.
Gemcitabine is generally a well-tolerated cyto-
static and its most frequent cutaneous side effects
are well documented, including alopecia, maculo-
papular eruption and are reported with a preva-
lence of 25.7–39%.1 Whereas, few other adverse
effects are less common and rarely reported; these
include pseudolymphoma,2 lipodermatosclerosis
reaction,1 linear IgA bullous dermatosis (LABD),7
limbs acronecrosis,8 erysipeloid rash developed in
lymphedema areas or following radiotherapy9,10
and scleroderma-like reaction.11 More severe drug-
induced reactions with gemcitabine, such as toxic
epidermal necrolysis and Stevens–Johnson syn-
drome, were reported during concurrent che-
motherapy and radiotherapy.12,13
We describe a further patient showing a cuta-
neous bullous lesions somedays following gemcita-
bine therapy. This bullous dermatosis is not
common and has been described in 1/1000–10,000
of cases treated with chemotherapy. Also, there
are neither histological findings of toxidermy nor
direct immunofluorescence deposit, and gemcita-
bine can be involved in this side effect; in fact,
although the half-life of elimination of gemcitabine
ranges from 11 to 26min and that of its metabolites
is from 0.7 to 12 h, Naranjo probability scale14
showed that the causal relationship of gemcitabine
treatment with cutaneous eruption is possible
(calculated scale ¼ 4).
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occurrence; in fact, gemcitabine is usually ex-
creted renally, its pharmacokinetics might be
altered by legs oedema, inactivation is so slower
and drug might accumulate in the subcutaneous
and cutaneous tissue, increasing local toxicity. This
explanation had been previously reported with
erysipeloid rash occurring in lymphedema areas.9
Some almost identical cases were reported with
LABD induced by gemcitabine7; in fact, this lesion is
an autoimmune, subepidermal, vesiculobullous
disease that has been commonly associated with
vancomycin therapy, appearing 24 h to 15 days
after the first drug dose and also rarely with
gemcitabine.7,15 In the case reported, lesions
aspects are similar to LABD, but the difference is
the lack of immunofluorescence positivity.
Peripheral oedema occurs in up to 20% of
patients treated with gemcitabine; the oedema is
typically mild, requiring discontinuation of the drug
in less than 1% of patients. Most patients require no
therapy. However, in cases of peripheral oedema of
grade II or higher, suspension of gemcitabine and
treatment with corticosteroids are often necessary,
and permanent discontinuation of gemcitabine may
be required on occasion.16
In our patient, no other causes of peripheral
oedema were found and thus, this had been
associated with gemcitabine therapy.
Incrimination of cisplatin also seems to be
unlikely as time course between the last cisplatin
administration and skin reaction of 45 days is so
long to make it the causative agent. Moreover,
calculated Naranjo score is equal to zero and thus,
the causative relationship is doubtful.
Gemcitabine appears more likely involved in this
skin reaction and pathologists should be aware
about any skin reactions during chemotherapeutic
agents administration in order to identify the cause
of toxicity and avoid misdiagnosis.References
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